Johnson Investment Counsel Inc. Has $2.04 Million Position in Repligen Co. (NASDAQ:RGEN)

Johnson Investment Counsel Inc. reduced its stake in Repligen Co. (NASDAQ:RGEN) by 6.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 14,146 shares of the biotechnology company’s stock after selling 1,035 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Repligen were worth $2,036,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the last quarter. First Turn Management LLC acquired a new position in shares of Repligen during the third quarter worth approximately $13,202,000. Thrivent Financial for Lutherans lifted its holdings in shares of Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after buying an additional 36,773 shares during the last quarter. Geneva Capital Management LLC lifted its holdings in shares of Repligen by 8.5% during the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock worth $20,638,000 after buying an additional 10,908 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its holdings in shares of Repligen by 11.9% during the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock worth $7,482,000 after buying an additional 5,337 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on RGEN shares. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group upped their price target on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Finally, TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Stock Up 7.4 %

Shares of NASDAQ RGEN opened at $147.13 on Wednesday. The stock has a market cap of $8.24 billion, a PE ratio of -288.49, a PEG ratio of 4.54 and a beta of 0.95. The business has a fifty day moving average of $157.16 and a two-hundred day moving average of $148.52. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $200.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.